Are you about to start your first biologic therapy?

You may be eligible to join the PrismRATM study

Changing the way RA is treated

Imagine knowing if a treatment will work before you take it. Roughly 1 in 3 people living with rheumatoid arthritis (RA) who are prescribed a biologic (anti-TNF) therapy such as Humira®, Enbrel®, Remicade®, Cimzia®, Inflectra®, Simponi®, or Simponi Aria® will adequately respond to treatment. Currently, there is no tool to predict which person will respond to these drugs. Scipher Medicine aspires to change this with PrismRATM, a new test that could improve how RA is treated.

PrismRATM is an experimental blood test that may predict non-response to biologic therapies in people living with RA. This could help patients get faster access to the right therapies, saving ‘non-responders’ time and potential side-effects caused while on ineffective drugs.

What's involved:

The purpose of the study, called the NETWORK-004 trial, is to evaluate the clinical performance of PrismRATM, an investigational blood test that identifies people who will not respond adequately to anti-TNF therapies before they start treatment.

This study doesn’t require additional office visits or experimental therapies. If you are considering or about to start taking a drug such as Humira®, Enbrel®, Remicade®, Cimzia®, Inflectra®, Simponi® you may be eligible to participate. As you progress through your treatment as prescribed by your doctor, small blood samples will be drawn during routine office visits. These samples, along with your doctor’s evaluations, will be analyzed to determine how you are responding to treatment, which is all that’s needed to change the way RA could be treated in the future.

You may be eligible to participate in the NETWORK-004 trial if you:
-are 18 or older with moderate to severe RA
-are currently taking Methotrexate
-have never previously taken an anti-TNF
-are willing to take an anti-TNF

Find out more and see if there’s a participating clinic near you.